Migraine

The CGRP inhibitor fremanezumab reduced both monthly migraine and monthly headache days among children aged 6 to 17 years with a favorable safety profile.

Your daily dose of the clinical news you may have missed.

A single 750 mg intravenous infusion of Lu AG09222 showed a 2-day difference in reducing monthly migraine day compared with placebo.

Use of the unique STS101 drug device combination proved safe, well tolerated, and effective with as needed use over 12 months, reported Satsuma Pharmaceuticals.

Help young patients with migraine (and their parents) get and stay prepared for the shift from home to college with this migraine survival kit checklist.

Your daily dose of the clinical news you may have missed.

Erenumab 140 mg safely and effectively induced remission in nonopioid MOH within 6 months in individuals for whom other preventive medications had failed.

Individuals with migraine who failed to respond to up to 4 previous migraine preventive treatments saw fewer monthly migraine and headache days after 1 infusion of Lu AG90222.

Based on its acceptance of the resubmission, FDA has assigned a PDUFA action goal date of January 31, 2025 for AXS-07.

Labeling for triptan medications warns of potential for ischemic events but is the concern theoretical or real? A new study tests the association.

AAN: 70% of participants reached ≥50% reduction in MMDs at weeks 13-16 that was consistent for 48 weeks in an interim analysis of a 156-week open-label trial.

The AHS recommends the migraine-specific preventive medications be prescribed first, with no requirements to "fail" other treatments for eligibility.

Your daily dose of the clinical news you may have missed.

Atogepant was associated with fewer monthly migraine days, fewer acute medication use days, and greater QoL compared with rimegepant after 12 weeks.

The phase 4 APPRAISE trial found greater efficacy with erenumab after failure with 1 or 2 other preventives vs ongoing treatment with the nonspecific oral agents.

Your daily dose of the clinical news you may have missed.

Women with migraine and persistent VMS faced double the risk of CVD and triple the risk of stroke, reported researchers.

Your daily dose of the clinical news you may have missed.

Which medications are most effective for acute migraine management? A recent study assessed which ones appeared to work best based on reported patient experience.

Common triggers, such as stress, travel, and disrupted routines, can impact patients with migraine this holiday season. Practical strategies and short-term preventive measures to help, here.

Which antihypertensive therapy options are most and least effective for patients with migraine? Get details, here.

Get details on which migraine treatments are the better option for women who are breastfeeding, and on ones to advise them to avoid.

An overview of safe treatment options for migraine attacks that may occur during pregnancy for primary care clinicians, here.

The device from Nexalin Technology outperformed placebo on key measures of pain relief, sleep quality, anxiety, and quality of life.

An overview of oral preventive medication options for migraine for primary care clinicians, here.